Skip to main content

AbbVie Inc. income statement

  • ABBV · NYSE
  • Pharmaceuticals
  • Biotechnology
  • S&P 500
$295.03+0.20%Close 13 Nov 2026 · Market value $524.5B

AbbVie Inc. reported revenue of $61.2 billion for fiscal year 2025 (the twelve months to 31 Dec 2025), up 8.6% from fiscal 2024. Net income was $4.23 billion and diluted earnings per share $2.36.

From AbbVie Inc.'s annual and quarterly reports, each period checked against accounting identities; a figure that does not pass is left blank. Fiscal years follow the company's calendar, the latest ending 31 Dec 2025. TTM is the last four reported quarters added up.

Annual

AbbVie Inc. income statement, annual
USDFY 2011FY 2012FY 2013FY 2014FY 2015FY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025TTM
Revenue$17.44B$18.38B$18.79B$19.96B$22.86B$25.64B$28.22B$32.75B$33.27B$45.80B$56.20B$58.05B$54.32B$56.33B$61.16B$66.01B
Revenue growth—+5.4%+2.2%+6.2%+14.5%+12.2%+10.1%+16.1%+1.6%+37.7%+22.7%+3.3%−6.4%+3.7%+8.6%—
Net interest income$20.00M−$84.00M−$278.0M−$391.0M−$686.0M−$965.0M−$1.00B−$1.14B−$1.51B−$2.28B−$2.38B−$2.04B−$1.68B−$2.16B−$2.63B−$2.68B
Cost of revenue$4.64B$4.51B$4.58B$4.43B$4.50B$5.83B$7.04B$7.72B$7.44B$15.39B$17.45B$17.41B$20.41B$16.90B$18.20B$17.35B
Gross profit$12.80B$13.87B$14.21B$15.53B$18.36B$19.80B$21.17B$25.04B$25.83B$30.42B$38.75B$40.64B$33.90B$39.43B$42.96B$48.67B
Gross margin73.4%75.5%75.6%77.8%80.3%77.2%75.0%76.4%77.6%66.4%69.0%70.0%62.4%70.0%70.2%73.7%
Selling, general and administrative$5.89B$4.99B$5.35B$7.72B$6.39B$5.88B$6.29B$7.40B$6.94B$11.30B$12.35B$15.26B$12.87B$14.75B$14.01B$15.19B
Operating income$3.62B$5.82B$5.66B$3.41B$7.54B$9.34B$9.54B$6.38B$12.98B$11.36B$17.92B$18.12B$12.76B$9.14B$15.07B$21.23B
Operating margin20.8%31.6%30.1%17.1%33.0%36.4%33.8%19.5%39.0%24.8%31.9%31.2%23.5%16.2%24.6%32.2%
Interest expense—$104.0M$299.0M$429.0M$719.0M$1.05B$1.15B$1.35B$1.78B$2.45B$2.42B$2.23B$2.22B$2.81B$2.89B$2.98B
Income before tax$3.67B$5.72B$5.33B$2.37B$6.64B$7.88B$7.73B$5.20B$8.43B$3.40B$12.99B$13.48B$6.25B$3.72B$6.60B$12.81B
Income tax expense$235.0M$450.0M$1.20B$595.0M$1.50B$1.93B$2.42B−$490.0M$544.0M−$1.22B$1.44B$1.63B$1.38B−$570.0M$2.36B$2.47B
Effective tax rate6.4%7.9%22.6%25.1%22.6%24.5%31.3%−9.4%6.5%−36.0%11.1%12.1%22.0%−15.3%35.8%19.2%
Net income$3.43B$5.28B$4.13B$1.77B$5.14B$5.95B$5.31B$5.69B$7.88B$4.62B$11.54B$11.84B$4.86B$4.28B$4.23B$10.34B
Net margin19.7%28.7%22.0%8.9%22.5%23.2%18.8%17.4%23.7%10.1%20.5%20.4%9.0%7.6%6.9%15.7%
Net income to common shareholders$3.43B$5.28B$4.13B—$5.12B$5.92B$5.28B$5.66B$7.84B$4.56B$11.47B$11.78B$4.82B$4.24B$4.19B$10.30B
EPS · diluted$2.18$3.35$2.56$1.10$3.13$3.63$3.30$3.66$5.28$2.72$6.45$6.63$2.72$2.39$2.36$5.81
Diluted weighted average shares1.6B1.6B1.6B1.6B1.6B1.6B1.6B1.5B1.5B1.7B1.8B1.8B1.8B1.8B1.8B1.8B
Basic weighted average shares1.6B1.6B1.6B1.6B1.6B1.6B1.6B1.5B1.5B1.7B1.8B1.8B1.8B1.8B1.8B1.8B
EBITDA$4.89B$6.97B$6.56B$4.20B$8.37B$10.53B$11.05B$8.15B$15.00B$17.83B$26.45B$26.58B$21.45B$17.52B$23.21B$28.94B
EBITDA margin28.0%37.9%34.9%21.0%36.6%41.1%39.1%24.9%45.1%38.9%47.1%45.8%39.5%31.1%38.0%43.8%
Depreciation & amortization$1.27B$1.15B$897.0M$786.0M$836.0M$1.19B$1.50B$1.76B$2.02B$6.47B$8.52B$8.47B$8.70B$8.39B$8.14B$7.71B
Stock-based compensation$163.0M$187.0M$212.0M$241.0M$282.0M$353.0M$365.0M$421.0M$430.0M$753.0M$692.0M$671.0M$747.0M$911.0M$955.0M$927.0M
Dividends per share——$2.00$1.75$2.10$2.35$2.63$3.95$4.39$4.84$5.31$5.71$5.99$6.29$6.65$6.92

Quarterly

AbbVie Inc. income statement, quarterly
USDQ4 FY2023Q1 FY2024Q2 FY2024Q3 FY2024Q4 FY2024Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025Q1 FY2026Q2 FY2026Q3 FY2026
Revenue$14.30B$12.31B$14.46B$14.46B$15.10B$13.34B$15.42B$15.78B$16.62B$15.00B$16.99B$17.40B
Net interest income−$378.0M−$453.0M−$506.0M−$591.0M−$610.0M−$627.0M−$678.0M−$667.0M−$655.0M−$645.0M−$679.0M−$700.0M
Cost of revenue$5.70B$4.09B$4.20B$4.21B$4.40B$4.00B$4.35B$5.30B$4.55B$4.22B$4.29B$4.29B
Gross profit$8.60B$8.22B$10.26B$10.25B$10.71B$9.34B$11.08B$10.47B$12.07B$10.78B$12.70B$13.12B
Gross margin60.1%66.7%70.9%70.9%70.9%70.0%71.8%66.4%72.6%71.9%74.7%75.4%
Selling, general and administrative$3.19B$3.31B$3.38B$4.21B$3.85B$3.29B$3.25B$3.57B$3.90B$3.58B$3.63B$4.09B
Operating income$3.19B$2.80B$4.00B$3.83B−$1.49B$3.73B$4.89B$1.90B$4.54B$3.99B$6.43B$6.27B
Operating margin22.3%22.7%27.6%26.5%−9.9%28.0%31.7%12.1%27.3%26.6%37.9%36.0%
Interest expense$564.0M$660.0M$726.0M$720.0M$702.0M$700.0M$740.0M$739.0M$714.0M$717.0M$746.0M$802.0M
Income before tax$1.21B$1.75B$2.15B$2.08B−$2.27B$1.66B$1.55B$714.0M$2.67B$1.04B$4.28B$4.83B
Income tax expense$388.0M$383.0M$773.0M$520.0M−$2.25B$372.0M$613.0M$526.0M$853.0M$342.0M$662.0M$609.0M
Effective tax rate32.0%21.8%36.0%25.0%99.0%22.4%39.4%73.7%32.0%32.9%15.5%12.6%
Net income$822.0M$1.37B$1.37B$1.56B−$22.00M$1.29B$938.0M$186.0M$1.82B$695.0M$3.61B$4.22B
Net margin5.7%11.1%9.5%10.8%−0.1%9.6%6.1%1.2%10.9%4.6%21.3%24.2%
Net income to common shareholders——$1.36B—−$32.00M$1.28B$928.0M$176.0M——$3.60B$4.21B
EPS · diluted$0.46$0.77$0.77$0.88−$0.02$0.72$0.52$0.10$1.02$0.39$2.03$2.37
Diluted weighted average shares1.8B1.8B1.8B1.8B1.8B1.8B1.8B1.8B1.8B1.8B1.8B1.8B
Basic weighted average shares1.8B1.8B1.8B1.8B1.8B1.8B1.8B1.8B1.8B1.8B1.8B1.8B
EBITDA$5.27B$4.87B$6.08B$5.92B$612.0M$5.77B$6.98B$4.00B$6.53B$5.93B$8.33B$8.16B
EBITDA margin36.9%39.6%42.1%41.0%4.1%43.3%45.3%25.3%39.3%39.5%49.0%46.9%
Depreciation & amortization$2.08B$2.07B$2.08B$2.09B$2.10B$2.04B$2.09B$2.09B$1.99B$1.94B$1.89B$1.89B
Stock-based compensation$125.0M$348.0M$218.0M$181.0M$164.0M$410.0M$179.0M$209.0M$157.0M$444.0M$166.0M$160.0M
Dividends per share$1.55$1.55$1.55$1.55$1.64$1.64$1.64$1.64$1.73$1.73$1.73$1.73

The main figures as JSON and plain text. See data and methodology.

ABBV in the terminal

Every line back twenty years, charts of any figure, segments and KPIs by quarter, valuation and alerts.